Organon & Co | OGN - Selling And Administration Expenses


Organon & Co reported $424M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Celltrion KRW 9.32B 3.39B Mar/2026
Cspc Pharmaceutical CNY 1.87B 95.62M Dec/2025
Deva Holding AS TRY 462.26M 48.18M Sep/2023
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Gilead Sciences USD 1.45B 326M Mar/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Kangmei Pharma CNY 237.06M 37.35M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Laboratorios Farma EUR 35.32M 2.75M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Merck USD 2.67B 180M Mar/2026
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Novartis USD 3.14B 296M Mar/2026
Organigram Holdings CAD 22.01M 14.28M Mar/2026
Organon & Co USD 424M 9M Mar/2026
Ovoca Bio EUR 617K 15K Dec/2025
Pharma Mar EUR 17.12M 1.82M Jun/2026
Qiagen NV USD 142.39M 11.49M Mar/2026
Sartorius EUR 221.3M 0 Jun/2026
Sino Biopharmaceutical CNY 7.54B 2.23B Jun/2025
Tilray USD 24.85M 1.7M Sep/2025
Zealand Pharma A/S 104M 12.19M Mar/2026